A. Sellmer

发表

Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.

T. Beckers, T. Ciossek, T. Maier, 2010, Journal of medicinal chemistry.

Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides: a SAR study on the bioisosterism of pyrimidine and imidazole.

S. Mahboobi, A. Sellmer, F. Böhmer, 2008, European journal of medicinal chemistry.

Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.

S. Mahboobi, A. Sellmer, O. Krämer, 2018, European journal of medicinal chemistry.

2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.

T. Beckers, T. Ciossek, T. Maier, 2007, Journal of medicinal chemistry.

Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases

T. Beckers, Mathias Schmidt, H. Fiebig, 2012 .

Development of Tubulin Inhibitors as Antimitotic Agents for Cancer Therapy

T. Beckers, S. Mahboobi, A. Sellmer, 2006 .

Synthesis and cytotoxic activity of 2-acyl-1H-indole-4,7-diones on human cancer cell lines.

T. Beckers, H. Fiebig, S. Mahboobi, 2005, European journal of medicinal chemistry.

Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.

S. Dietrich, M. Tomicic, G. Schneider, 2017, Cellular signalling.

Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells.

W. Sippl, M. Christmann, S. Mahboobi, 2021, Cell chemical biology.

3-Bromo-4-(1H-3-indolyl)-2,5-dihydro-1H-2,5-pyrroledione derivatives as new lead compounds for antibacterially active substances.

S. Mahboobi, A. Sellmer, E. Eichhorn, 2006, European journal of medicinal chemistry.

Enantioselective synthesis and biological investigation of tetrahydro‐β‐carboline‐based HDAC6 inhibitors with improved solubility

S. Mahboobi, A. Sellmer, Elisabeth Grünstein, 2019, Archiv der Pharmazie.

Generation and Assessment of Fusions Between HDACi and TKi.

S. Mahboobi, A. Sellmer, Bernadette Pilsl, 2017, Methods in molecular biology.

A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer.

B. Kuster, R. Rad, S. Heinzlmeir, 2021, Bioorganic chemistry.

10-Aminomethylene-1,8-dihydroxy-9(10H)-anthracenones: Inhibitory action against 5-lipoxygenase and the growth of HaCaT cells

A. Sellmer, H. Prinz, K. Müller, 1997 .

Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.

R. Straub, S. Mahboobi, A. Sellmer, 2018, Journal of medicinal chemistry.

Synthesis of Naturally Occurring Pyrazine and Imidazole Alkaloids from Botryllus LeachiRID=”a”ID=”a” Dedicated to Prof. G. Märkl on the occasion of his 75th birthday

D. Schollmeyer, S. Mahboobi, A. Sellmer, 2004 .

Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth.

A. Sellmer, W. Wiegrebe, K. Müller, 1999, Journal of natural products.

[4-(imidazol-1-yl)thiazol-2-yl]phenylamines. A novel class of highly potent colchicine site binding tubulin inhibitors: synthesis and cytotoxic activity on selected human cancer cell lines.

T. Beckers, Mathias Schmidt, T. Maier, 2006, Journal of medicinal chemistry.

Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase.

T. Beckers, C. Schächtele, S. Teller, 2002, Journal of medicinal chemistry.

Electron Impact Induced Fragmentation of Aromatic Alkoxyimines II [5]. Formation and Transformation of Heterocyclic Radical Cations in the Gas Phasea

A. Sellmer, W. Wiegrebe, K. Mayer, 2003 .

Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.

C. Stocking, F. Heidel, T. Fischer, 2006, Journal of medicinal chemistry.

2-Arylamino-4-amino-5-aroylthiazoles. "One-pot" synthesis and biological evaluation of a new class of inhibitors of tubulin polymerization.

A. Brancale, G. Basso, G. Viola, 2009, Journal of medicinal chemistry.

A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.

B. Kuster, Susan Klaeger, H. Polzer, 2020, European journal of medicinal chemistry.

Human platelet lysate as validated replacement for animal serum to assess chemosensitivity.

F. Butter, S. Mahboobi, A. Sellmer, 2018, ALTEX.

HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer

R. Rad, D. Saur, R. Schmid, 2017, Oncogene.

HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1

G. Schneider, A. Sellmer, O. Krämer, 2019, Cancers.

HSP90 is necessary for the ACK1-dependent phosphorylation of STAT1 and STAT3.

L. Kenner, A. Haitel, S. Mahboobi, 2017, Cellular signalling.

Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3

A. Piée-Staffa, T. Nikolova, W. Brenner, 2021, Archives of Toxicology.

Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells

M. Christmann, B. Kaina, F. Grebien, 2016, Archives of Toxicology.

Antibacterial activity of a novel series of 3-bromo-4-(1H-3-indolyl)-2,5-dihydro-1H-2,5-pyrroledione derivatives--an extended structure-activity relationship study.

S. Mahboobi, A. Sellmer, M. Winkler, 2008, European journal of medicinal chemistry.

Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones.

S. Mahboobi, A. Sellmer, E. Eichhorn, 2007, Bioorganic & medicinal chemistry.

Drugging the HDAC6-HSP90 interplay in malignant cells.

S. Mahboobi, A. Sellmer, O. Krämer, 2014, Trends in pharmacological sciences.

Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.

F. Totzke, T. Beckers, H. Fiebig, 2012, Bioorganic & medicinal chemistry.

Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.

S. Dietrich, M. Tomicic, G. Schneider, 2017, Cellular signalling.

Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.

T. Beckers, T. Ciossek, T. Maier, 2009, Journal of medicinal chemistry.

Biological and structural investigation of tetrahydro-β-carboline-based selective HDAC6 inhibitors with improved stability.

C. Bařinka, Linda Schäker-Hübner, S. Mahboobi, 2024, European journal of medicinal chemistry.